{"filings":[{"id":1592320,"accession_number":"0001493152-26-032938","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2026-07-13T12:05:22+00:00","items":["1.01","3.02","3.03","5.01","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma to combine with GH Power; MTNB holders get 9% of combined co; sells Nano to Azurity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business Combination Agreement with GH Power: MTNB shareholders receive 0.1 Pubco share per MTNB share; GH Power holders get ~91% of combined entity.","Stock Purchase Agreement: Matinas Nano sold to Azurity for up to $21.5M cash ($4M upfront, $17.5M milestones) plus mid-single-digit royalty on MAT2203.","Series D PIPE closed: $575,000 gross proceeds from sale of convertible preferred stock and warrants; requires stockholder approval for conversion shares.","Post-closing board: 5 directors (1 from MTNB, 4 from GH Power); CEO and CFO expected from GH Power; lock-up 180 days for insiders.","Termination fees: $1M payable by MTNB to GH Power if MTNB terminates for superior offer; $1M payable by GH Power to MTNB if GH Power terminates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-13","daily_digest_url":"/daily/2026-07-13","daily_digest_rank":2},{"id":1306398,"accession_number":"0001493152-26-030342","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2026-06-26T21:15:40+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma receives NYSE American non-compliance notice; granted plan period through Oct 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $3.02M as of March 31, 2026 fails the $4M minimum under Section 1003(a)(ii) of NYSE American Guide.","Company also continues to be non-compliant with the $6M equity standard under Section 1003(a)(iii) as previously disclosed.","NYSE American accepted the Company's plan to regain compliance, granting a plan period through October 2, 2027.","Common stock will continue trading on NYSE American under symbol MTNB during the plan period; delisting proceedings possible if not compliant by deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93848,"accession_number":"0001493152-26-015170","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Matinas BioPharma receives NYSE American delisting notice for low equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $4.83M as of Dec 31, 2025, below the $6M threshold for five years of losses.","Company has until May 2, 2026 to submit a plan to regain compliance; cure period up to 18 months.","Independent auditor included a going-concern paragraph in the 10-K for the year ended Dec 31, 2025.","No immediate impact on listing; common stock continues trading on NYSE American pending review.","If plan is rejected, delisting proceedings will commence; company may appeal per NYSE rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105793,"accession_number":"0001493152-26-003445","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Matinas BioPharma CFO Keith Kucinski resigns; CEO Jerome Jabbour named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Kucinski resigned as CFO effective January 17, 2026, to pursue other opportunities.","Board appointed CEO and Chairman Jerome D. Jabbour as interim CFO effective January 22, 2026.","Jabbour retains roles as Chairman, President, and CEO; assumes principal financial and accounting officer duties.","No change in Jabbour's compensation or other material terms in connection with appointment.","No family relationships or transactions between Jabbour and any director or officer requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122075,"accession_number":"0001493152-25-027529","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Matinas BioPharma amends CEO Jabbour's employment agreement extending retention bonus window to June 30, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retention bonus trigger extended from Mar 31, 2026 to Jun 30, 2026; 2/3 paid upon signing definitive agreement, 1/3 at closing.","CEO guaranteed 2025 annual bonus at target, payable by Feb 1, 2026, subject to continued employment.","Change in Control definition expanded to include material change to primary business.","Cause and Good Reason definitions modified; company confirms no grounds for Cause exist as of Dec 12, 2025.","Company to reimburse CEO up to $20,000 for legal fees incurred for amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122074,"accession_number":"0001493152-25-024691","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Matinas BioPharma CFO Keith Kucinski to resign effective Jan 17, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Kucinski notified his resignation as CFO on Nov 18, 2025.","Resignation effective Jan 17, 2026; he is pursuing other opportunities.","No disagreement with the Company regarding operations, policies, or practices.","No successor named; CEO Jerome Jabbour signed the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138779,"accession_number":"0001641172-25-024520","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Matinas BioPharma exchanges 466,666 warrants for common stock; cancels $17.50 strike warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into Warrant Exchange Agreements on Aug 15, 2025 with certain warrant holders.","Issued 466,666 shares of common stock in exchange for an equal number of warrants with $17.50 exercise price.","Warrants were originally issued on April 5, 2024; after exchange, all such warrants are cancelled.","Exchange was exempt from registration under Section 3(a)(9); no cash consideration involved.","Shares issued without restrictive legends and are freely tradable under federal securities laws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138778,"accession_number":"0001641172-25-022445","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Matinas BioPharma increases authorized common stock to 500M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares doubled from 250M to 500M effective Aug 6, 2025.","Shareholder approval obtained at 2025 annual meeting on June 23, 2025.","Total authorized capital stock is now 510M shares (500M common + 10M preferred).","Certificate of Amendment filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156234,"accession_number":"0001641172-25-016064","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve reverse split up to 1:199, authorized shares to 500M, and new equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; advisory vote on executive compensation passes with 5.56M for, 0.11M against.","Reverse stock split authorized in range of 1-for-2 to 1-for-199 over two years; 6.94M for, 0.54M against.","Authorized common shares increased from 250M to 500M; 6.91M for, 0.57M against.","2025 Equity Incentive Plan approved with 5.39M for, 0.28M against, 1.81M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156233,"accession_number":"0001641172-25-008417","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.03","5.02","5.08","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma reduces quorum threshold, adds change-in-control bonuses for CEO/CFO, schedules annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board reduced stockholder quorum from majority to one-third of voting power to facilitate meetings.","CEO Jerome Jabbour eligible for retention bonus up to $299,000 if change in control occurs before March 31, 2026.","CFO Keith Kucinski eligible for retention bonus up to $166,400 under same change-in-control terms.","2025 annual meeting set for June 23, 2025; record date May 1, 2025.","Stockholder proposals and nominations must be received by May 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156232,"accession_number":"0001641172-25-003271","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Matinas BioPharma closes $1.65M second tranche of Series C preferred & warrant offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing on April 8, 2025 raised $1.65M from sale of 1,650 Series C Convertible Preferred shares.","Total offering raises $3.3M; preferred initially convertible into up to 5.63M common shares, warrants for 11.26M additional shares.","Securities issued without registration under Section 4(a)(2) and Regulation D; proceeds for general corporate purposes.","First closing of 1,650 shares occurred on February 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156231,"accession_number":"0001641172-25-002818","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Matinas BioPharma shareholders approve issuance of up to 16.9M shares and ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 passed with 88% of votes cast; authorizes up to 16,894,212 common shares upon conversion of Series C Preferred and warrants.","Proposal 2 ratified EisnerAmper LLP as independent auditor for FY2025 with 95% of votes cast.","Proposal 3 to adjourn meeting if needed approved with 90% of votes cast.","Shareholders representing 52.47% of outstanding shares were present at the Special Meeting on April 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.15,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174696,"accession_number":"0001493152-25-010416","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Matinas BioPharma Chairman Eric Ende resigns from Board effective March 14","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Ende resigned as Board member and Chairman on March 14, 2025.","Resignation is due to other professional obligations, not a disagreement.","No replacement for Chairman or Board seat has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174695,"accession_number":"0001493152-25-009775","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma appoints Keith Murphy and Edward Neugeboren to board; two directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Natasha Giordano and Matthew Wikler resigned from the Board effective Feb 11, 2025, not due to any disagreement.","Keith Murphy (Organovo Executive Chairman) appointed director, Chair of Governance Committee, Compensation Committee member.","Edward Neugeboren (Cronus Pharma Chief Strategy Officer) appointed director, Chair of Compensation, Audit Committee member.","Neugeboren qualifies as audit committee financial expert; both are independent under NYSE and SEC rules.","New directors bring significant healthcare, biotech, and capital markets experience; effective March 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174694,"accession_number":"0001493152-25-006481","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","3.02","3.03","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Matinas raises $3.3M via Series C preferred and warrants; appoints Dr. Robin Smith to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of $1.65M for 1,650 Series C shares; second $1.65M closing subject to shareholder approval by April 10, 2025.","Series C convertible at $0.586/share; warrants exercisable at $0.6446 for 5 years post-shareholder approval.","Proceeds to reduce operating expenses and explore strategic alternatives for MAT2203 and other options.","Dr. Robin L. Smith appointed to board; Herbert J. Conrad resigns as founding Chairman and retires.","Company required to file resale registration statement by 15th day after 2024 10-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174693,"accession_number":"0001493152-25-005948","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Matinas BioPharma director Herbert Conrad resigns due to retirement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Herbert Conrad resigned from Board of Directors effective February 6, 2025.","Conrad also stepped down from Audit and Nominating/Corporate Governance Committees.","Resignation was not due to any material disagreement or change in company direction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174692,"accession_number":"0001493152-25-005302","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Matinas BioPharma appoints Evelyn D'An as independent director and Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Evelyn D'An appointed to board effective February 5, 2025 as independent director and Audit Committee Chair.","Ms. D'An is a former Ernst & Young partner with 18 years of experience, currently President of D'An Financial Services.","She also serves on boards of Zoomcar (ZCAR), Backblaze (BLZE), and GHD Group (private).","No related party transactions; compensated under standard non-employee director plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174691,"accession_number":"0001493152-25-003632","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":[],"status":"ready","headline":"Matinas BioPharma director James Scibetta resigns from board effective Jan 21, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James S. Scibetta resigned from the Board of Directors effective January 21, 2025.","He also resigned from his positions on the Audit and Compensation Committees.","Resignation was due to other professional obligations, not a material disagreement.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174690,"accession_number":"0001493152-25-001782","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Matinas BioPharma receives NYSE American notice for failure to hold 2024 annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On January 6, 2025, Matinas received NYSE American notice for failing to hold 2024 annual meeting, violating Section 704.","Company plans to hold annual meeting no later than December 31, 2025 to cure deficiency.","Common stock continues trading on NYSE American with '.BC' indicator during cure period.","Risks disclosed include sale of MAT 2203 and evaluation of alternatives including winddown or dissolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191654,"accession_number":"0001493152-24-048036","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":[],"status":"ready","headline":"Director Kathryn Penkus Corzo resigns from Matinas BioPharma board effective Nov 22, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Kathryn Penkus Corzo resigned from Board effective Nov 22, 2024, citing other professional obligations.","Resignation not due to any material disagreement or change in company direction.","She also resigned from Compensation and Nominating and Corporate Governance Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191653,"accession_number":"0001493152-24-043130","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.05","2.06","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma terminates MAT2203 partnership, cuts 80% workforce, ceases development, considers dissolution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership negotiations for MAT2203 global rights terminated; prospective partner withdrew.","80% workforce reduction of 15 positions, including CMO, CBO, and CTO, effective Oct 31, 2024.","All product development ceased; exploring asset sale of MAT2203 or winddown/dissolution of the company.","CMO James Ferguson terminated; severance ~$500k (12 months base salary plus benefits)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191652,"accession_number":"0001493152-24-042277","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":[],"status":"ready","headline":"Matinas BioPharma CDO resigns; CMO and VP Clinical Dev to assume duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Development Officer Theresa Matkovits resigned effective October 23, 2024, to pursue another opportunity.","Resignation not due to material disagreement or change in company direction.","James J. Ferguson (CMO) and Susan Johansson (VP Clinical Dev) will fill her responsibilities.","Company continues to work toward partnership on MAT2203, its oral amphotericin B formulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208117,"accession_number":"0001493152-24-034729","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Matinas BioPharma effects 1:50 reverse stock split; trading halted on NYSE American, risk of delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Aug 30, 2024, Matinas executed a 1:50 reverse stock split and reduced authorized shares from 500M to 250M.","Trading of MTNB halted on NYSE American on Aug 27 due to low price; expects to resume split-adjusted on Sep 3 subject to exchange approval.","If post-split share price fails to meet NYSE American requirements, exchange could suspend trading or delist the stock.","No fractional shares issued; stockholders with fractional entitlements were rounded up to the next whole share.","Reverse split approved by stockholders on Nov 1, 2023; Board authorized filing on Aug 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208116,"accession_number":"0001493152-24-034098","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Matinas BioPharma receives NYSE American trading halt due to low price; plans 1-for-50 reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trading of MTNB common stock halted by NYSE American on August 27, 2024 due to low trading price.","Halt to remain until reverse stock split (1-for-50) is consummated; split effective 5:00 PM EST on August 30, 2024.","Split-adjusted trading expected to begin September 3, 2024, subject to NYSE American approval.","If post-split price does not meet Section 1003(f)(v) requirements, NYSE could suspend trading and delist shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208115,"accession_number":"0001493152-24-033263","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Matinas BioPharma announces 1-for-50 reverse stock split effective Aug 30, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-50 reverse stock split and reduction of authorized shares from 500M to 250M.","Effective at 5:00 PM EST on Aug 30, 2024; split-adjusted trading under symbol MTNB begins Sep 3.","Fractional shares rounded up to nearest whole share; no cash paid for fractions.","Company believes split will help maintain NYSE American listing; may pursue Nasdaq uplisting later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208114,"accession_number":"0001493152-24-032189","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Matinas BioPharma Q2 net loss $5.7M ($0.02/sh); signs non-binding MAT2203 term sheet","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2024 was $5.7 million ($0.02 per share), compared to $6.1 million ($0.03) in Q2 2023.","Cash, cash equivalents and marketable securities were $14.3 million as of June 30, 2024; raised $10M in April offering.","Signed non-binding term sheet for global licensing rights to develop and commercialize oral MAT2203 for invasive aspergillosis.","31 patients enrolled in MAT2203 Compassionate/Expanded Use Access Program; 7 additional under evaluation.","LNC platform showed tumor inhibition in animal models; additional optimization needed before selecting product candidate."],"consensus_eps_estimate":-1.275,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225676,"accession_number":"0001493152-24-018428","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Matinas BioPharma Q1 2024 net loss $5.8M; raises $10M in April, expects cash into Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $0 vs $1.1M in Q1 2023; net loss $5.8M ($0.03 per share).","Cash and equivalents $8.1M at March 31, 2024; subsequent $10M registered direct offering in April 2024.","Active partnership discussions to advance MAT2203 into Phase 3 ORALTO trial in invasive aspergillosis.","Compassionate use program has enrolled 22 patients with severe fungal infections; LNC platform abstracts at ASGCT."],"consensus_eps_estimate":-1.53,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225675,"accession_number":"0001493152-24-013255","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Matinas BioPharma raises $10M in registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 33,333,334 shares and warrants at $0.30/unit; gross proceeds ~$10M.","Warrants exercisable at $0.35/share for 5.5 years from issuance, starting 6 months post-closing.","Proceeds to be used for working capital and general corporate purposes.","Offering expected to close April 5, 2024; A.G.P./Alliance Global Partners sole placement agent.","Directors and officers subject to 90-day lock-up on securities transfers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244834,"accession_number":"0001493152-24-011625","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Matinas BioPharma updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished updated corporate presentation dated March 28, 2024 under Regulation FD.","Presentation to be used at conferences and investor meetings; specific content not provided.","No financial results, guidance, or operational milestones disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244833,"accession_number":"0001493152-24-011509","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Matinas BioPharma reports 2023 net loss $22.9M; cash runway only through Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $1.1M from $3.2M; net loss per share $0.11 vs $0.10 prior year.","Cash and equivalents $13.8M at Dec 31, 2023, down from $28.8M; company sees funding only through Q3 2024.","FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis.","Compassionate use program: 19 patients enrolled; most with renal recovery after switching from AmBisome; 8 completed with complete resolution.","Preclinical LNC-docetaxel shows comparable efficacy to IV-docetaxel with no weight loss in mice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244832,"accession_number":"0001493152-24-011077","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma oral LNC-docetaxel shows no toxicity in mouse study; 8x higher dose tolerated without weight loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total docetaxel delivered orally via LNC was >8x IV dose by Day 22; all IV mice lost avg 20% weight, LNC mice maintained weight normal.","One IV-docetaxel mouse died (32% weight loss); LNC-docetaxel mice had no mortality and weight statistically same as saline controls.","Daily oral LNC-docetaxel dose 50% higher and total drug 3.5x greater than prior study that showed comparable anti-tumor activity to IV-docetaxel.","Company plans further evaluation of higher doses in additional tumors and other toxic chemotherapies using LNC platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244831,"accession_number":"0001493152-24-010921","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma reports complete clinical response in 3 fusarium patients with oral MAT2203","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three patients with azole-resistant invasive fusarium infection achieved complete clinical response after oral MAT2203 treatment.","Two of these patients had not yet achieved complete resolution at the time of the prior 19-patient update.","Patients could not tolerate IV amphotericin B due to nephrotoxicity; oral MAT2203 resolved infections over 2 weeks to 6 months.","Results bolster confidence for upcoming Phase 3 ORALTO trial in invasive aspergillosis with limited treatment options.","MAT2203 is not yet licensed or approved anywhere globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244830,"accession_number":"0001493152-24-010901","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Matinas BioPharma regains NYSE American continued listing compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notification on March 21, 2024, resolving low selling price deficiency under Section 1003(f)(v).","Common stock demonstrated sustained price improvement, curing the non-compliance.","'.BC' indicator discontinued at market open on March 22, 2024; removed from noncompliant issuers list.","NYSE American confirmed continued listing standard is now satisfied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244829,"accession_number":"0001493152-24-007772","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas reports positive MAT2203 compassionate use data: 12 of 15 patients improved, all completers resolved.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19 patients enrolled in compassionate-use program for oral antifungal MAT2203; 15 evaluable.","12 of 15 patients had complete clinical resolution or objective improvement in infection markers.","All 5 patients who completed full treatment (2 weeks to 1 year) had complete resolution with no relapse.","All patients who transitioned from AmBisome due to renal toxicity saw return to baseline renal function.","Patients treated at 9 major institutions including Johns Hopkins, NIH, Memorial Sloan Kettering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244828,"accession_number":"0001493152-24-007115","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA agrees on Phase 3 trial design for Matinas' MAT2203 in invasive aspergillosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis; primary endpoint all-cause mortality at day 42.","Trial will enroll ~216 adults with limited treatment options; 2:1 randomization to oral MAT2203 vs continued AmBisome + SOC.","Key secondary endpoint: superiority of MAT2203 over AmBisome for treatment-related toxicities leading to treatment changes.","Enrollment expected to begin H2 2024, complete in ~24 months at ~65 sites across US, Europe, South America, Middle East, Asia Pacific.","CEO says FDA alignment provides certainty to advance partnership discussions; product not yet approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244827,"accession_number":"0001493152-24-001771","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Matinas BioPharma updates corporate presentation; no specific disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation dated January 9, 2024, for use at conferences and investor meetings.","No financial results, pipeline updates, or material agreements were disclosed in the filing.","The presentation is attached as Exhibit 99.1 but its content is not summarized in the 8-K.","Ticker: MTNB (NYSE American). Event is a routine Regulation FD disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262278,"accession_number":"0001493152-23-046183","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas reports oral LNC-oligonucleotides show TNFα reduction in colitis model; psoriasis markers improve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Orally LNC-formulated small oligonucleotide targeting TNFα reduced serum TNFα by 37% in DSS-induced colitis model.","Active LNC formulation significantly improved clinical disease activity scores at key time points in colitis study.","In IMQ-induced psoriasis model, LNC-delivered IL-17A oligonucleotide lowered skin tissue IL-17A mRNA and improved redness/scaling.","Plans to present additional tissue/histologic analyses at future scientific meetings.","CEO highlights potential for oral delivery of extra-hepatic small oligonucleotides as differentiating platform feature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262277,"accession_number":"0001493152-23-045661","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma receives FDA feedback on Phase 3 protocol for MAT2203; meeting set for early Q1 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA provided written comments on revised Phase 3 protocol for MAT2203 in invasive aspergillosis with limited treatment options.","Company invited to meeting early Q1 2024 to finalize Phase 3 study design.","Partnership discussions for MAT2203 remain ongoing.","Goal is single Phase 3 registration trial for approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262276,"accession_number":"0001493152-23-041978","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Matinas BioPharma updates corporate presentation; no specifics available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation updated as of November 20, 2023.","Presentation intended for use at conferences and investor meetings.","Exhibit 99.1 attached; full content not provided in accessible text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262275,"accession_number":"0001493152-23-040136","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma oral LNC docetaxel shows tumor reduction comparable to IV in melanoma model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral LNC docetaxel reduced tumor volume 63% (high dose) and 57% (low dose) vs 68% for IV docetaxel at Day 14.","No systemic toxicity observed over 10 days; body weight and hematologic parameters stable.","Company plans further studies in other tumor models and longer treatment regimens to confirm safety.","Also plans to evaluate LNC formulations for small oligonucleotide anti-tumor activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262274,"accession_number":"0001493152-23-039902","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Matinas BioPharma reports Q3 net loss $6.1M; FDA supports MAT2203 Phase 3 with LPAD pathway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.1M ($0.03 per share) in Q3 2023 vs $5.5M in Q3 2022; no revenue vs $1.1M from BioNTech in prior year.","Cash $18.2M at Sep 30, 2023; runway into Q3 2024; seeking non-dilutive BARDA funding.","FDA agreed MAT2203 Phase 3 design for invasive aspergillosis with limited treatment options; acknowledged LPAD registration pathway.","FDA open to superiority composite endpoint to strengthen commercial positioning without increasing study size (<200 patients).","Patient with Candida krusei achieved complete clinical resolution after 2 weeks on MAT2203; new fusarium patient enrolled at Vanderbilt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":1096000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262273,"accession_number":"0001493152-23-039180","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Matinas BioPharma shareholders approve reverse stock split and reelect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 7 director nominees elected; Eric Ende received 57.9M for, 10.1M withheld; 59.1M broker non-votes.","Say-on-pay proposal approved: 53.3M for, 12.0M against, 2.7M abstain.","Ratification of EisnerAmper as auditor passed: 121.9M for, 3.1M against, 2.1M abstain.","Amendment to effect reverse stock split (1:2 to 1:50) and reduce authorized shares to 250M approved: 93.0M for, 31.1M against.","Total shares represented at meeting: 127.1M, or 58.5% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279470,"accession_number":"0001493152-23-033498","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma receives NYSE American deficiency notice for low price; must cure by Mar 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American deficiency letter for non-compliance with Section 1003(f)(v) due to 30-day avg closing price below $0.20.","Must demonstrate sustained price improvement or effect reverse stock split by March 21, 2024 to regain compliance.","Common stock continues trading on NYSE American under symbol MTNB; no immediate delisting.","Company is actively engaging with Exchange and developing plans to cure within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279469,"accession_number":"0001493152-23-033131","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Matinas BioPharma updates corporate presentation for investor meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation updated as of September 20, 2023 for use at conferences.","No specific financial or operational details disclosed in the filing body.","Investors should review the exhibit for any changes to strategy or pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279468,"accession_number":"0001493152-23-027349","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Matinas BioPharma Q2 net loss $6.1M; FDA sets 700-patient bar for MAT2203 first-line","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 revenue $0 (vs $1.1M in Q2 2022); net loss $6.1M ($0.03/sh) vs $5.9M.","Cash and securities $22.5M at June 30, down from $28.8M; runway into Q3 2024.","FDA requires ~700-patient non-inferiority trial (10% mortality margin) for first-line MAT2203 approval.","Compassionate use: 15-year-old with leukemia and resistant mucor/aspergillus improved on MAT2203, no nephrotoxicity.","Internal RNAi show in vitro activity; in vivo oral LNC data expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1096000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297863,"accession_number":"0001493152-23-016160","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma concludes BioNTech mRNA collaboration, plans Phase 3 trial for MAT2203 antifungal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BioNTech oral mRNA collaboration ended; in vivo oral study showed no activity, but systemic delivery and stability demonstrated.","Company plans to submit revised Phase 3 trial design for MAT2203 in aspergillosis and other IFIs in Q2 2023.","Seven patients with IFIs treated under compassionate use; oral MAT2203 showed safety and efficacy in diverse infections.","Cash position sufficient to fund operations into second half of 2024.","Expanded collaboration with National Resilience for mRNA/oligonucleotide delivery; initial data expected Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297862,"accession_number":"0001493152-23-012718","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma: compassionate use patient complete resolution of rare fungal infection with MAT2203; Phase 3 planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient treated with MAT2203 achieved complete clinical resolution of R. mucilaginosa infection after 6 months and regained use of foot.","MAT2203 was well-tolerated with no renal adverse effects; patient's renal function improved and remained at baseline.","Prior IV-amphotericin B was discontinued due to electrolyte abnormalities and toxicities; MAT2203 allowed outpatient monitoring.","Company in final stages of planning Phase 3 program for MAT2203 with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318114,"accession_number":"0001493152-23-007732","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Matinas BioPharma reports 2022 net loss $21M, cash $28.8M; LNC platform updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.2M from BioNTech collaboration, vs $33K in 2021.","Net loss $21.0M ($0.10/share) vs $23.7M ($0.11/share) in 2021.","Cash and marketable securities $28.8M at Dec 31, 2022, sufficient into Q2 2024.","Anticipates Q2 2023 in vivo data from BioNTech and National Resilience collaborations.","Planned FDA meeting for MAT2203 Phase 3; potential BARDA/NIH funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318113,"accession_number":"0001493152-23-002910","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma reports $28.8M cash, focuses LNC on nucleic acids, pauses MAT2203 Phase 3 for BARDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash of $28.8M at Dec 31, 2022, down from $49.6M at Dec 31, 2021; runway projected into Q2 2024.","LNC platform achieves intracellular delivery of larger nucleic acids, mRNA stable >10 weeks at 4°C, low cytotoxicity.","MAT2203 Phase 3 for cryptococcal meningitis paused pending BARDA evaluation; FDA meeting planned Q2 2023 for second Phase 3 study in four invasive fungal infections (approx. 100 patients).","BioNTech collaboration: in vivo studies start Q1 2023, data expected Q2 2023; Resilience initial data in Q2/Q3 2023; Genentech extended through 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318112,"accession_number":"0001493152-23-001237","cik":1582554,"company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Matinas BioPharma partners with Resilience to explore oral nucleic acid delivery via LNC platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Material Transfer and Evaluation Agreement with National Resilience for oral delivery of nucleic acids.","Research program includes design, formulation, optimization, and in vitro/in vivo testing of nucleic acids with LNC platform.","Collaboration is distinct from ongoing work with BioNTech, allowing simultaneous platform development.","No financial terms disclosed; partnership aims to demonstrate LNC platform capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5060890.321697467,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-12T23:59:59+00:00|318112"}